MIT's 'Mini Livers' Could Revolutionize Treatment for Failing Organs

Engineers at MIT have created tiny, injectable 'mini livers' that could help patients with failing organs. These lab-grown clusters of liver cells are designed to support liver function without replacing the entire organ. The breakthrough offers hope for thousands waiting for transplants.

The new treatment involves injecting clusters of liver cells that act as 'satellite livers'. Once inside the body, they take over essential functions, producing key proteins needed for survival. In tests on mice, the injected cells stayed active for at least two months.

Over 10,000 Americans with chronic liver disease are currently on the transplant waiting list. Many more are deemed too unwell to qualify for surgery. Donor organs are in short supply, leaving patients with few options.

Unlike traditional transplants, this approach avoids major surgery. The 'mini livers' work alongside the patient's existing organ, boosting its function rather than replacing it entirely.

The technology could provide a lifeline for those who cannot access or withstand a full transplant. With further testing, it may reduce reliance on donor organs and improve outcomes for liver disease patients. The next steps will involve larger trials to confirm safety and effectiveness in humans.